Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines

Danica P. Galonić and David Y. Gin
Additional contact information
Danica P. Galonić: Harvard Medical School
David Y. Gin: Memorial Sloan-Kettering Cancer Center

Nature, 2007, vol. 446, issue 7139, 1000-1007

Abstract: Abstract Therapeutic vaccines derived from carbohydrate antigen–adjuvant combinations are a promising approach for cancer immunotherapy. One of the critical limitations in this area is access to sufficient quantities of tumour-associated carbohydrate antigens and glycoconjugate adjuvants. At present, availability of the complex oligosaccharide constructs that are needed for the systematic design and evaluation of novel vaccine formulations relies on de novo chemical synthesis. The use of both state-of-the-art and emerging glycosylation technologies has led to significant advances in this field, allowing the clinical exploration of carbohydrate-based antigens in the treatment of cancer.

Date: 2007
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature05813 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:446:y:2007:i:7139:d:10.1038_nature05813

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature05813

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().